Complement Inhibition for Geographic Atrophy: A Tempting Target with Mixed Results
Related Experiment Video
Updated: Oct 30, 2025
Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
Published on: February 12, 2018
Jonathan B Lin1, Omar A Halawa1, Joan W Miller1
1Department of Ophthalmology, Massachusetts Eye and Ear and Harvard Medical School, Boston, MA 02114, USA.
Insights
Age-related macular degeneration (AMD) is a leading cause of blindness. Targeting the complement system, particularly with complement factor H (CFH) gene variants, is a key strategy for geographic atrophy (GA) treatment.
Area of Science:
- Ophthalmology
- Genetics
- Immunology
Background:
- Age-related macular degeneration (AMD) is a primary cause of vision loss in elderly individuals.
- A significant genetic risk factor for AMD is the complement factor H (CFH) gene polymorphism (Y402H).
- The strong association between the Y402H variant and AMD highlights the complement system's role in disease pathogenesis.
Purpose of the Study:
- To review the historical context and current status of complement inhibition as a therapeutic strategy for geographic atrophy (GA) in AMD.
- To analyze the potential benefits and drawbacks of using complement inhibitors for GA treatment.
- To identify critical questions that need resolution for complement inhibition to become a standard AMD therapy.
Main Methods:
- Literature review and synthesis of existing research on complement pathways in AMD.
- Analysis of data from randomized clinical trials on complement inhibition for GA.
- Discussion of genetic risk factors, complement dysregulation, and therapeutic strategies.
Main Results:
- The Y402H variant in the CFH gene is strongly linked to AMD, implicating the complement system.
- Complement inhibition is being explored as a treatment to slow GA progression.
- Current clinical trial results for complement inhibition in GA are mixed, indicating a need for further research.
Conclusions:
- Complement dysregulation is a plausible contributor to AMD pathogenesis.
- Complement inhibition presents a potential therapeutic avenue for geographic atrophy, but its efficacy and optimal application require further investigation.
- Addressing key research questions is essential before complement inhibition can be widely adopted for AMD treatment.
Abstract:
Age-related macular degeneration (AMD) is a leading cause of blindness in older adults. One of the strongest genetic risk factors for AMD is a complement factor H (CFH) gene polymorphism characterized by a tyrosine-histidine change at amino acid position 402 (Y402H). The magnitude of this association between the Y402H variant and AMD is among the strongest that has been identified for any complex, multifactorial human disease. This strong association has motivated researchers to investigate a potential link between various elements of the complement pathway and AMD pathogenesis. Given the possible contribution of complement dysregulation to AMD, complement inhibition has emerged as a therapeutic strategy for slowing geographic atrophy (GA). Randomized clinical trials thus far have yielded mixed results. In this article, we provide the historical context for complement inhibition as a strategy for treating GA, discuss potential advantages and disadvantages of complement inhibition, and highlight the questions that must be addressed before complement inhibition can take center stage as a therapy for AMD.
